EGFR and non-small cell lung carcinoma: In the phase II APOLLO trial, aumolertinib showed adequate effectiveness in EGFR T790M‐positive NSCLC patients, with a CNS ORR of 60.9% and a median CNS PFS of 10.8 months [9].